section name header

Information

[Section Outline]

An autoimmune neuromuscular junction (NMJ) disorder resulting in weakness and fatigability of skeletal muscles, usually due to autoantibodies directed against acetylcholine receptors (AChRs).

Clinical Features !!navigator!!

May present at any age but peak incidences occur in women in their twenties and thirties and in men in their fifties and sixties. Symptoms fluctuate throughout the day and are provoked by exertion. Characteristic distribution: cranial muscles (eyelids, extraocular muscles, facial weakness, “nasal” or slurred speech, dysphagia); in 85%, limb muscles (often proximal and asymmetric) become involved. Reflexes and sensation normal. May be limited to extraocular muscles only. Complications: aspiration pneumonia (weak bulbar muscles), respiratory failure (weak chest wall muscles), exacerbation of myasthenia due to administration of drugs with NMJ blocking effects (quinolones, macrolides, aminoglycosides, procainamide, propranolol, nondepolarizing muscle relaxants).

Pathophysiology !!navigator!!

Anti-AChR antibodies reduce the number of available AChRs at the NMJ. Postsynaptic folds are flattened or “simplified,” with resulting inefficient neuromuscular transmission. During repeated or sustained muscle contraction, decrease in amount of ACh released per nerve impulse (“presynaptic rundown,” a normal occurrence), combined with disease-specific decrease in postsynaptic AChRs, results in pathologic fatigue. Thymus is abnormal in 75% of pts (65% hyperplasia, 10% thymoma). Other autoimmune diseases may coexist: Hashimoto's thyroiditis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus.

Differential Diagnosis !!navigator!!

Lambert-Eaton syndrome (autoantibodies to calcium channels in presynaptic motor nerve terminals): reduced ACh release; may be associated with malignancy

Neurasthenia: weakness/fatigue without underlying organic disorder

Drug-induced myasthenia:penicillamine may cause myasthenia gravis (MG); resolves weeks to months after discontinuing drug. Checkpoint inhibitors for treatment of cancer also implicated more recently.

Botulism: toxin inhibits presynaptic ACh release; most common form is food-borne.

Diplopia from an intracranial mass lesion: compression of nerves to extraocular muscles or brainstem lesions affecting cranial nerve nuclei

Hyperthyroidism

Progressive external ophthalmoplegia: seen in rare mitochondrial disorders that can be detected with muscle biopsy

Laboratory Evaluation !!navigator!!

  • AChR antibodies: levels do not correlate with disease severity; 85% of all MG pts are positive; only 50% with pure ocular findings are positive; positive antibodies are diagnostic. Muscle-specific kinase (MuSK) antibodies present in 40% of AChR antibody-negative pts with generalized MG.
  • Tensilon (edrophonium) test: a short-acting anticholinesterase-look for rapid and transient improvement of strength, now mainly reserved for those with negative antibody testing. False-positive (placebo response, motor neuron disease) and false-negative tests occur. Atropine IV should be on hand if symptoms such as bradycardia occur.
  • EMG: low-frequency (2-4 Hz) repetitive stimulation produces rapid decrement in amplitude (>10%) of evoked motor responses.
  • Chest CT/MRI: search for thymoma.
  • Consider thyroid and other studies (e.g., ANA) for associated autoimmune disease.
  • Measurements of baseline respiratory function are useful.
TREATMENT

Myasthenia Gravis

(See Fig. 197-1. Algorithm for the Management of Myasthenia Gravis)

  • The anticholinesterase drug pyridostigmine (Mestinon) titrated to assist pt with functional activities (chewing, swallowing, strength during exertion); usual initial dose of 30-60 mg 3-4 times daily; long-acting tablets help at night, but have variable absorption so are not reliable during the day. Muscarinic side effects (diarrhea, abdominal cramps, salivation, nausea) blocked with atropine/diphenoxylate or loperamide if required.
  • Plasmapheresis or IV immune globulin (IVIg; 400 mg/kg per day for 5 days) provides temporary boost for seriously ill pts; used to improve condition prior to surgery or during myasthenic crisis (see below).
  • Thymectomy improves likelihood of long-term remission in adult pts (85% improve; of these, 35% achieve drug-free remission); benefit is usually delayed by months to years; unclear if there is benefit in pts with pure ocular disease, antibody negative pts, children, or those age >55.
  • Glucocorticoids are a mainstay of chronic immunosuppressive treatment; begin prednisone at low dose (15-25 mg/d), increase by 5 mg/d every 2-3 days until marked clinical improvement or dose of 50-60 mg/d is reached. Maintain high dose for about a month, then decrease to alternate-day regimen. Immunosuppressive drugs (mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, and occasionally cyclophosphamide) may spare dose of prednisone required long-term to control symptoms.
  • A growing body of evidence indicates that rituximab is effective in many MG pts, especially those with MuSK antibody.
  • Myasthenic crisis is defined as an exacerbation of weakness, usually with respiratory failure, sufficient to endanger life; expert management in an intensive care setting essential as is prompt treatment with IVIg or plasmapheresis to hasten recovery.
  • A number of drugs may exacerbate MG, potentially leading to crisis, and therefore should be avoided (Table 197-1 Drugs with Interactions in Myasthenia Gravis (MG)).

Outline

Section 14. Neurology